Abstract: In various examples, a three-stage pipeline is used to automate the generation of paired parts (or components) in assemblies. The pipeline includes a first contact surface extraction stage, in which a set of contact surfaces is extracted from a first part based on attributes identified by a vision language model (VLM) and/or another type of machine learning model from a visual and/or another representation of the first part. The pipeline also includes a shape completion stage, in which the contact surfaces are used to condition the operation of a diffusion model and/or another type of three-dimensional (3D) generative model in generating a shape for a second part that is complementary to the first part. The pipeline further includes a clearance specification stage, in which the shape of a given part is updated to meet a minimum clearance distance from the other part.

Abstract: A method of determining a patient's HPD status comprising the steps of a) examining a patient tumor sample for the expression level of HPD-diagnostic biomarkers, and b) determining whether the signature of the biomarkers is similar to that of a HPD positive signature is disclosed.

Abstract: A method of determining a patient's HPD status comprising the steps of a) examining a patient tumor sample for the expression level of HPD-diagnostic biomarkers, and b) determining whether the signature of the biomarkers is similar to that of a HPD positive signature is disclosed.

Abstract: The present invention provides novel gene signature associated with immune checkpoint inhibitor (ICT) named ImmuneCells.Sig which is predicative of ICT outcomes of melanoma patients which is significantly more accurate than all previously reported ICT response signatures. The ImmuneCells.Sig can be used as an accurate predictor of ICT response and may be used to determine if a patient will be susceptible and respond to ICT treatment.

Abstract: Methods for inhibiting proliferation of a cell, particularly a cancer cell are provided. The method comprises increasing intracellular levels of one or more wild-type ras proteins in the cell. In one aspect, the method comprises introducing and expressing a nucleic molecule that encodes a wild-type ras protein in the cell. In another aspect, intracellular levels of one more ras proteins are increased by introducing one or more wild-type ras proteins into the cell. The present invention also relates to the therapeutic use of wild-type ras proteins or nucleic acids that encode one or more wild-type ras proteins in the treatment of tumors or cancer, or prophylactically to prevent formation of tumors or cancer. Methods of characterizing or evaluating cancer in a humans or other mammals are provided. In one embodiment, the method comprises assaying for a loss of function mutation in one or more endogenous ras alleles in the genome of tumor cells obtained from the subject.